A Phase 3 interventional study of entecavir in Hepatitis B, Chronic, sponsored by Bristol-Myers Squibb. Completed at 32 sites in 9 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2012-05-31.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies testing entecavir in Hepatitis B, Chronic — 3 open to participants now, 3 under way, none of them phase 3. entecavir · Hepatitis B, Chronic.
Among the 64 studies testing entecavir in Hepatitis B, Chronic, this one is the 31st largest by enrollment of the 61 interventional ones that give a count, is one of 7 that started in 2007, is one of 13 in phase 3, and was the 7th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →3 of the 64 studies testing entecavir in Hepatitis B, Chronic are open now, in 1 country. Recruiting first, the newest first:
Ascentage Pharma Group Inc. · Sites in China
Ages 18+
Qing-Lei Zeng
Ages 3–6
Qing-Lei Zeng
Ages 3–6
By country, each count listing its studies:
entecavir: first FDA approval 2005 (BARACLUDE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 10 · Phase 3 13 · Phase 4 33
First in 2001; this study’s year is marked. 7 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 109 is close to the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 109 across the 61 interventional studies. Of the 40 that completed or were terminated, 15 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 64 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
24 studies in Hepatitis B, Chronic by Bristol-Myers Squibb: none open now, none under way, none of them phase 3. Of 23 finished, 11 (48%) have results posted.
Among the 24 studies in Hepatitis B, Chronic by Bristol-Myers Squibb, this one is the 10th largest by enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2007, is one of 11 in phase 3, and was the 7th registered.
Bristol-Myers Squibb’s Hepatitis B, Chronic studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 64 studies testing entecavir in Hepatitis B, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 24 in Hepatitis B, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical research study is to learn if the study drug entecavir will prevent the recurrence of hepatitis B virus (HBV) in participants who receive an orthotopic liver transplant (OLT) due to HBV infection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: entecavir
Tablets, Oral, 1 mg, once daily, up to 72 weeks
Also known as: Baraclude, BMS-200475
Percentage of Participants With HBV Deoxyribonucleic Acid (DNA) => 50 IU/mL by Polymerase Chain Reaction (PCR) at Week 72
HBV DNA assessments were performed using the Roche COBAS® TaqMan High+Pure system (HPS) assay. HBV DNA =\> 50 IU/mL = approximately =\> 300 copies/mL.
Time frame: At 72 weeks
Number of Participants With HBV DNA by PCR >= 50 IU/mL Through Week 72
HBV DNA assessments were performed using the Roche COBAS® TaqMan High+Pure system (HPS) assay. HBV DNA =\> 50 IU/mL = approximately =\> 300 copies/mL.
Time frame: At baseline (day 1), week 12, 24, 36, 48, 60, and 72
Distribution of ALT Levels Through 72 Weeks: Overall
ALT is an enzyme present in serum and various tissues of the body, associated commonly with the liver. Elevated levels of ALT often suggests existence of medical problems which includes viral hepatitis. Normal range varies from laboratory to laboratory. Values of 5-60 U/L is usually considered normal. ALT abnormality = \>1.25 x ULN (upper limit of normal).
Time frame: On Day 1 (baseline) and at week 4, 12, 24, 36, 48, 60, 72
Percentage of Participants With HBV DNA < 50 IU/mL (Approximately 300 Copies/mL) by PCR at the End of Post-dosing Follow-up
HBV DNA assessments were to be performed using the Roche COBAS® TaqMan AmpliPrep assay. HBV DNA \< 50 IU/mL = approximately 300 copies/mL.
Time frame: At 72 weeks + 24 weeks follow-up
Percentage of Participants With HBeAg Loss at Week 72 (for HBeAg-positive Participants)
HBeAg is a hepatitis B viral protein. HBeAg loss = HBeAg-negative at the specified analysis week.
Time frame: At week 72
Percentage of Participants With HBeAg Seroconversion at Week 72 (for HBeAg-positive Participants)
HBeAg is a hepatitis B viral protein. HBeAg Seroconversion = HBeAg Loss and Presence of Hepatitis B e Antibody (HBeAb).
Time frame: At week 72
Percentage of Participants With HBsAg Loss at Week 72
HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBsAg loss = HBsAg-negative at the specified analysis week.
Time frame: At week 72
Percentage of Participants With HBsAg Seroconversion at Week 72
HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBs seroconversion is defined as HBsAg loss with positive HBsAb.
Time frame: At week 72
Percentage of Participants With HBsAg Recurrence At Week 72
HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBsAg recurrence is defined as having detectable HBsAg among participants who have already experienced loss of HBsAg on-treatment. HBsAg recurrence = HBsAg-positive at the specified analysis week.
Time frame: At week 72
Total Bilirubin at Week 72
Bilirubin measures are used to diagnose or monitor liver functioning or diseases that include hepatitis. Viral hepatitis is one of the condition in which bilirubin levels are elevated. Normal range varies from laboratory to laboratory. Bilirubin abnormality : =\> 1.1 x ULN mg/dL.
Time frame: At week 72
Prothrombin Time (PT) at Week 72
Prothrombin, a liver protein, plays an important role in the extrinsic pathway of clotting. Increased prothrombin time indicates abnormal liver functioning. Normal prothrombin time varies from laboratory to laboratory. Generally, normal prothrombin time varies between 10 to 13.2 seconds. Abnormal PT: \> 1.01 x ULN.
Time frame: At week 72
Number of Participants With Liver Rejection Through Week 72
Time frame: Through week 72
Number of Participants With Re-transplantation Through Week 72
Time frame: Through week 72
Participants With Adverse Events (AE), Serious Adverse Events (SAE), and Discontinuations From Study Drug Due to AEs (On-treatment [OT] and Off-treatment Follow-up [OF])
AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or an overdose. Toxicity grading by modified WHO grade system. Grade (GR) 2=moderate; GR3=severe; GR4=very severe. OT=from start of dosing to end of dosing+5 days; OF=from end of dosing+6 days to start of other anti-HBV therapy or end of follow-up.
Time frame: OT:From start of dosing through Week 72 + 5 days; OF:End of OT through 24-weeks follow-up
Number of Participants With Laboratory Abnormalities On-treatment (OT) and Off-Treatment Follow-up(OF): Hematology (All Grades)
Criteria for hematology abnormalities were: Hemoglobin : \<11.0 g/dL; White Blood Cells : \<4000/mm\^3; Neutrophils : \<1500/mm\^3; Platelets : \< 99,000/mm\^3; International Normalized Ratio (INR) : increase \>= 0.5 from baseline.
Time frame: OT:From start of dosing through Week 72 + 5 days; OF:End of OT through 24-weeks follow-up
Number of Participants With Laboratory Abnormalities On-treatment (OT) and Off-Treatment (OF) Follow-up: Serum Chemistry (All Grades)
Normal ranges are local lab data and vary according to the site. Criteria for laboratory abnormalities:ALT:\>1.25xULN;AST:\>1.25xULN;ALP:\>1.25xULN;Total Bilirubin:\>1.1xULN;Serum Lipase:\>1.10xULN;Creatinine:\>1.1xULN;Blood Urea Nitrogen:\>1.25xULN;Hyperglycemia:\>116mg/dL;Hypoglycemia:\<64mg/dL;Hyponatremia:\<132meq/L;Hypernatremia:\>148meq/L;Hypokalemia:\<3.4meq/L;hyperkalemia:\>5.6meq/L;Hypochloremia:\<93meq/L;Hyperchloremia:\>113meq/L;Albumin: Decrease \>= 1g/dL from baseline and \< 3 g/dL. HYPER=value\>ULN(upper limit of normal). HYPO=value\<LLN (lower limit of normal).
Time frame: OT:From start of dosing through Week 72 + 5 days; OF:End of OT through 24-weeks follow-up
A total of 109 participants were enrolled at 27 investigative sites.
| Milestone | Entecavir (ETV) |
|---|---|
| Started | 65 |
| Discontinued prior to week 72 visit | 10 |
| Discontinued at or after week 72 visit | 0 |
| Completed | 55 |
| Not completed | 10 |
| Withdrew: Death | 4 |
| Withdrew: Other reason | 2 |
| Withdrew: Poor/non-compliance | 2 |
| Withdrew: Subject no longer meets study criteria | 2 |
| Milestone | Entecavir (ETV) |
|---|---|
| Started | 5 |
| Completed | 1 |
| Not completed | 4 |
| Withdrew: Followup no longer required per protocol | 1 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Poor/non-compliance | 1 |
HBV DNA assessments were performed using the Roche COBAS® TaqMan High+Pure system (HPS) assay. HBV DNA =\> 50 IU/mL = approximately =\> 300 copies/mL.
| percentage of participants | Entecavir (ETV) |
|---|---|
| Percentage of Participants With HBV Deoxyribonucleic Acid (DNA) => 50 IU/mL by Polymerase Chain Reaction (PCR) at Week 72 | 0 (0.0 to 5.9) |
ALT is an enzyme present in serum and various tissues of the body, associated commonly with the liver. Elevated levels of ALT often suggests existence of medical problems which includes viral hepatitis. Normal range varies from laboratory to laboratory. Values of 5-60 U/L is usually considered normal. ALT abnormality = \>1.25 x ULN (upper limit of normal).
| U/L | Entecavir (ETV) |
|---|---|
| Baseline | 158.7 ± 36.20 |
| Week 4 | 61.2 ± 10.12 |
| Week 12 | 28.4 ± 2.66 |
| Week 24 (n=59) | 28.4 ± 3.37 |
| Week 36 (n=58) | 41.2 ± 8.20 |
| Week 48 (n=57) | 24.9 ± 1.91 |
| Week 60 (n=53) | 30.6 ± 4.04 |
| Week 72 (n=54) | 26.9 ± 2.81 |
HBV DNA assessments were to be performed using the Roche COBAS® TaqMan AmpliPrep assay. HBV DNA \< 50 IU/mL = approximately 300 copies/mL.
No measurements were reported for this outcome.
HBeAg is a hepatitis B viral protein. HBeAg loss = HBeAg-negative at the specified analysis week.
| percentage of participants | Entecavir (ETV) |
|---|---|
| Percentage of Participants With HBeAg Loss at Week 72 (for HBeAg-positive Participants) | 100 (59.0 to 100.0) |
HBeAg is a hepatitis B viral protein. HBeAg Seroconversion = HBeAg Loss and Presence of Hepatitis B e Antibody (HBeAb).
| percentage of participants | Entecavir (ETV) |
|---|---|
| Percentage of Participants With HBeAg Seroconversion at Week 72 (for HBeAg-positive Participants) | 0 (0.0 to 41.0) |
HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBsAg loss = HBsAg-negative at the specified analysis week.
| percentage of participants | Entecavir (ETV) |
|---|---|
| Percentage of Participants With HBsAg Loss at Week 72 | 96.7 (88.7 to 99.6) |
HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBs seroconversion is defined as HBsAg loss with positive HBsAb.
| percentage of participants | Entecavir (ETV) |
|---|---|
| Percentage of Participants With HBsAg Seroconversion at Week 72 | 80.3 (68.2 to 89.4) |
HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBsAg recurrence is defined as having detectable HBsAg among participants who have already experienced loss of HBsAg on-treatment. HBsAg recurrence = HBsAg-positive at the specified analysis week.
| percentage of participants | Entecavir (ETV) |
|---|---|
| Percentage of Participants With HBsAg Recurrence At Week 72 | 3.3 (0.4 to 11.3) |
Bilirubin measures are used to diagnose or monitor liver functioning or diseases that include hepatitis. Viral hepatitis is one of the condition in which bilirubin levels are elevated. Normal range varies from laboratory to laboratory. Bilirubin abnormality : =\> 1.1 x ULN mg/dL.
| mg/dL | Entecavir (ETV) |
|---|---|
| Total Bilirubin at Week 72 | 0.79 ± 0.079 |
Prothrombin, a liver protein, plays an important role in the extrinsic pathway of clotting. Increased prothrombin time indicates abnormal liver functioning. Normal prothrombin time varies from laboratory to laboratory. Generally, normal prothrombin time varies between 10 to 13.2 seconds. Abnormal PT: \> 1.01 x ULN.
| seconds | Entecavir (ETV) |
|---|---|
| Prothrombin Time (PT) at Week 72 | 13.32 ± 0.305 |
| participants | Entecavir (ETV) |
|---|---|
| Number of Participants With Liver Rejection Through Week 72 | 18 |
| participants | Entecavir (ETV) |
|---|---|
| Number of Participants With Re-transplantation Through Week 72 | 3 |
AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or an overdose. Toxicity grading by modified WHO grade system. Grade (GR) 2=moderate; GR3=severe; GR4=very severe. OT=from start of dosing to end of dosing+5 days; OF=from end of dosing+6 days to start of other anti-HBV therapy or end of follow-up.
| participants | Entecavir (ETV) |
|---|---|
| Death-OT | 4 |
| SAEs-OT | 36 |
| SAEs-OF (n=5) | 0 |
| Discontinuation due to AEs-OT | 0 |
| Any AE-OT | 62 |
| Any AE-OF (n=5) | 0 |
| Related AEs-OT | 11 |
| Grade 2 - 4 related AEs-OT | 8 |
| Grade 3 - 4 AEs-OT | 30 |
Criteria for hematology abnormalities were: Hemoglobin : \<11.0 g/dL; White Blood Cells : \<4000/mm\^3; Neutrophils : \<1500/mm\^3; Platelets : \< 99,000/mm\^3; International Normalized Ratio (INR) : increase \>= 0.5 from baseline.
| participants | Entecavir (ETV) |
|---|---|
| HEMOGLOBIN-OT | 56 |
| HEMOGLOBIN-OF (n=5) | 1 |
| WHITE BLOOD CELLS-OT | 50 |
| WHITE BLOOD CELLS-OF (n=5) | 2 |
| NEUTROPHILS (Includes absolute bands)-OT | 24 |
| NEUTROPHILS (Includes absolute bands)-OF (n=5) | 1 |
| PLATELETS-OT | 40 |
| PLATELETS-OF (n=5) | 2 |
| INR-OT (n=63) | 30 |
| INR-OF (n=4) | 0 |
Normal ranges are local lab data and vary according to the site. Criteria for laboratory abnormalities:ALT:\>1.25xULN;AST:\>1.25xULN;ALP:\>1.25xULN;Total Bilirubin:\>1.1xULN;Serum Lipase:\>1.10xULN;Creatinine:\>1.1xULN;Blood Urea Nitrogen:\>1.25xULN;Hyperglycemia:\>116mg/dL;Hypoglycemia:\<64mg/dL;Hyponatremia:\<132meq/L;Hypernatremia:\>148meq/L;Hypokalemia:\<3.4meq/L;hyperkalemia:\>5.6meq/L;Hypochloremia:\<93meq/L;Hyperchloremia:\>113meq/L;Albumin: Decrease \>= 1g/dL from baseline and \< 3 g/dL. HYPER=value\>ULN(upper limit of normal). HYPO=value\<LLN (lower limit of normal).
| participants | Entecavir (ETV) |
|---|---|
| ALANINE AMINOTRANSFERASE (ALT)-OT | 54 |
| ALT-OF (n=4) | 0 |
| ASPARTATE AMINOTRANSFERASE (AST)-OT | 56 |
| AST-OF (n=4) | 0 |
| ALKALINE PHOSPHATASE (ALP)-OT | 34 |
| ALP-OF (n=4) | 1 |
| ALBUMIN-OT (n=64) | 51 |
| ALBUMIN-OF (n=3) | 0 |
| TOTAL BILIRUBIN-OT | 57 |
| TOTAL BILIRUBIN-OF (n=4) | 0 |
| SERUM LIPASE-OT (n=64) | 37 |
| SERUM LIPASE-OF (n=3) | 1 |
| CREATININE-OT | 43 |
| CREATININE-OF (n=4) | 0 |
| BLOOD UREA NITROGEN-OT | 43 |
| BLOOD UREA NITROGEN-OF (n=4) | 0 |
| HYPERGLYCEMIA-OT (n=64) | 52 |
| HYPERGLYCEMIA-OF (n=3) | 0 |
| HYPOGLYCEMIA-OT (n=64) | 15 |
| HYPOGLYCEMIA-OF (n=3) | 0 |
| HYPERNATREMIA-OT | 7 |
| HYPERNATREMIA-OF (n=4) | 0 |
| HYPONATREMIA-OT | 14 |
| HYPONATREMIA-OF (n=4) | 0 |
| HYPERKALEMIA-OT | 15 |
| HYPERKALEMIA-OF (n=4) | 0 |
| HYPOKALEMIA-OT | 22 |
| HYPOKALEMIA-OF (n=4) | 0 |
| HYPERCHLOREMIA-OT | 11 |
| HYPERCHLOREMIA-OF (n=4) | 0 |
| HYPOCHLOREMIA-OT | 7 |
| HYPOCHLOREMIA-OF (n=4) | 0 |
HBV DNA assessments were performed using the Roche COBAS® TaqMan High+Pure system (HPS) assay. HBV DNA =\> 50 IU/mL = approximately =\> 300 copies/mL.
| participants | Entecavir (ETV) |
|---|---|
| Baseline | 3 (1.0 to 13.7) |
| Week 12 (n = 54) | 0 (0.0 to 6.6) |
| Week 24 (n = 58) | 0 (0.0 to 6.2) |
| Week 36 (n = 10) | 0 (0.0 to 30.8) |
| Week 48 (n = 49) | 0 (0.0 to 7.3) |
| Week 60 (n = 48) | 0 (0.0 to 7.4) |
| Week 72 (n = 49) | 0 (0.0 to 7.3) |
Collected over From start of dosing through Week 72 + 5 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Entecavir (ETV) | — | 36/65 (55.4%) | 58/65 (89.2%) |
| Event | Entecavir (ETV) |
|---|---|
| Renal failure acuteRenal and urinary disorders | 3/65 |
| Hepatic artery thrombosisHepatobiliary disorders | 3/65 |
| Aspartate aminotransferase increasedInvestigations | 2/65 |
| DiarrhoeaGastrointestinal disorders | 2/65 |
| Bile duct stenosisHepatobiliary disorders | 2/65 |
| Alanine aminotransferase increasedInvestigations | 2/65 |
| VomitingGastrointestinal disorders | 2/65 |
| CholangitisHepatobiliary disorders | 2/65 |
| PyrexiaGeneral disorders | 2/65 |
| NauseaGastrointestinal disorders | 2/65 |
| Event | Entecavir (ETV) |
|---|---|
| HypertensionVascular disorders | 22/65 |
| DiarrhoeaGastrointestinal disorders | 18/65 |
| Abdominal painGastrointestinal disorders | 17/65 |
| HyperglycaemiaMetabolism and nutrition disorders | 15/65 |
| HeadacheNervous system disorders | 13/65 |
| AscitesGastrointestinal disorders | 13/65 |
| InsomniaPsychiatric disorders | 13/65 |
| ConstipationGastrointestinal disorders | 12/65 |
| Back painMusculoskeletal and connective tissue disorders | 12/65 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 11/65 |
| Age Continuous(years) | Entecavir (ETV) |
|---|---|
| Median | 51.0 (23 to 68) |
| Age, Customized(participants) | Entecavir (ETV) |
|---|---|
| 21-64 years | 60 |
| >=65 years | 5 |
| Sex: Female, Male(Participants) | Entecavir (ETV) |
|---|---|
| Female | 12 |
| Male | 53 |
| Race/Ethnicity, Customized(participants) | Entecavir (ETV) |
|---|---|
| Asian | 24 |
| Black/African American | 7 |
| Native Hawaiian/Other Pacific Islander | 1 |
| White | 25 |
| Other | 8 |
| Race/Ethnicity, Customized(participants) | Entecavir (ETV) |
|---|---|
| Hispanic/Latino | 0 |
| Not Hispanic/Latino | 14 |
| Region of Enrollment(participants) | Entecavir (ETV) |
|---|---|
| Argentina | 2 |
| Australia | 5 |
| Brazil | 12 |
| France | 12 |
| Italy | 6 |
| Korea, Republic of | 7 |
| Spain | 3 |
| Taiwan | 4 |
| United States | 14 |
| HBV DNA by PCR(log10 IU/mL) | Entecavir (ETV) |
|---|---|
| Median | 0.8 (0.8 to 3.7) |
| Hepatitis B Surface Antigen(participants) | Entecavir (ETV) |
|---|---|
| Positive | 61 |
| Negative | 4 |
6 further baseline measures are reported on the registry.
The record gives a start of Apr 2007, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.
Results were first posted in May 2012, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Entecavir